Improvement of the Coxsackievirus B3 (CVB3)-induced mice-myocarditis model by development of a pancreas-attenuated virus

被引：0
作者：
Pryshliak, M. [1 ]
Pinkert, S. [1 ]
Hazini, A. [1 ]
Fechner, H. [1 ]
机构：
[1] Tech Univ Berlin, Berlin, Germany
来源：
HUMAN GENE THERAPY | 2016年 / 27卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P423
引用
收藏
页码：A174 / A174
页数：1
相关论文
共 50 条
  • [41] Viral myocarditis induced by Coxsackievirus B3 in A.BY/SnJ mice: Analysis of changes in the myocardial proteome
    Hammer, Elke
    Phong, Truong Quoc
    Steil, Leif
    Klingel, Karin
    Salazar, Manuela Gesell
    Bernhardt, Joerg
    Kandolf, Reinhard
    Kroemer, Heyo K.
    Felix, Stephan B.
    Voelker, Uwe
    [J]. PROTEOMICS, 2010, 10 (09) : 1802 - 1818
  • [42] Dicer-1 Prevents Coxsackievirus B3 (CVB3) Infection of the Heart by Inhibiting the Viral Replication in a RNaseIII Domain Dependent Manner
    Machida, Mitsuyo
    Uyesugi, Arthur
    Pokala, Vineel
    Yajima, Toshitaka
    [J]. CIRCULATION, 2012, 126 (21)
  • [43] The outcome of coxsackievirus B3-(CVB3-) induced myocarditis is influenced by the cellular immune status
    Leipner, C
    Grün, K
    Borchers, M
    Stelzner, A
    [J]. HERZ, 2000, 25 (03) : 245 - 248
  • [44] The Outcome of Coxsackievirus B3-(CVB3-) Induced Myocarditis is Influenced by the Cellular Immune Status
    Carola Leipner
    Katja Grün
    Michael Borchers
    Axel Stelzner
    [J]. Herz, 2000, 25 : 245 - 248
  • [45] A study of drug candidates derived from pleconaril for inhibiting coxsackievirus B3 (Cvb3) by ADMET, molecular docking, molecular dynamics and retrosynthesis
    Moukhliss, Youness
    Koubi, Yassine
    Alaqarbeh, Marwa
    Alsakhen, Nada
    Hamzeh, Samer
    Maghat, Hamid
    Sbai, Abdelouahid
    Bouachrine, Mohammed
    Lakhlifi, Tahar
    [J]. NEW JOURNAL OF CHEMISTRY, 2022, 46 (21) : 10154 - 10161
  • [46] TREATMENT OF COXSACKIEVIRUS B3 MYOCARDITIS BY IMMUNOACTIVE PEPTIDE IN AN ANIMAL-MODEL
    SATO, Y
    MATSUMORI, A
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 65 (01): : 65 - 69
  • [47] A Novel Oncolytic Viral Therapy Using Coxsackievirus B3 (CVB3) for Human Pancreatic Cancer Including Cancer-associated Fibroblasts
    Ogata, Hisanobu
    Imaizumi, Akira
    Fujioka, Yutaka
    Shimizu, Hiroyuki
    Hirata, Yusuke
    Matsuzawa, Atsushi
    Tsuruta, Toshihisa
    Niiro, Hiroaki
    Onishi, Hideya
    Nakamura, Masafumi
    Tani, Kenzaburo
    [J]. ANTICANCER RESEARCH, 2024, 44 (12) : 5215 - 5218
  • [48] Expression of noncollagenous extracellular matrix genes in myocardium of mice with coxsackievirus B3 myocarditis
    Guo, Q
    Zhao, CZ
    Chen, RC
    Yang, YZ
    Li, SJ
    Ge, JB
    Chen, HZ
    [J]. FASEB JOURNAL, 2005, 19 (04) : A532 - A532
  • [49] α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis
    Wu, C. Y.
    Feng, Y.
    Qian, G. C.
    Wu, J. H.
    Luo, J.
    Wang, Y.
    Chen, G. J.
    Guo, X. K.
    Wang, Z. J.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 162 (01) : 178 - 187
  • [50] Roles of miRNA21 in Coxsackievirus B3 (CVB3)-induced cardiac microvascular endothelial cells apoptosis via modulating the target gene of PDCD4
    Chen, R. Z.
    Yu, Y.
    Li, M. H.
    Yu, Y.
    Yang, Y. Z.
    Zou, Y. Z.
    Ge, J. B.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 708 - 708
12345